U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 10 results

Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Arhalofenate is a uricosuric drug which lowers serum urate by blocking its reabsorption by the proximal tubules of the kidney. Arhalofenate activity is mediated by inhibition of URAT1, OAT4 and OAT10. Additionally, arhalofenate has been suggested to ...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


(3,5-DIBROMO-4-HYDROXYPHENYL)(2,3-DIHYDRO-4H-PYRIDO[4,3-B][1,4]OXAZIN-4-YL)METHANONE (UR-1102/URC-1022) is currently under development for the management of hyperuricaemia in gout. It is a selective URAT1 inhibitor with Ki of 57 nM showing higher ur...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. Verinurad specifically inhibits URAT1 with a potency of 25 nM. High affinity inhibition of uric aci...
Status:
US Previously Marketed
First approved in 2015

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In gout patients, Lesinurad lowe...
Status:
US Previously Marketed
First approved in 1959

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Sulfinpyrazone was approved by the U.S. Food and Drug Administration (FDA) on May 13, 1959. It was developed and marketed as Anturane® by Novartis. Sulfinpyrazone is an oral uricosuric agent (pyrazolone derivative) used to treat chronic or intermitte...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)


Benzarone is a human uric acid transporter 1 inhibitor and causes hepatotoxicity.
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Arhalofenate is a uricosuric drug which lowers serum urate by blocking its reabsorption by the proximal tubules of the kidney. Arhalofenate activity is mediated by inhibition of URAT1, OAT4 and OAT10. Additionally, arhalofenate has been suggested to ...
Status:
US Previously Marketed
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In gout patients, Lesinurad lowe...
Status:
US Previously Marketed
First approved in 2015

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In gout patients, Lesinurad lowe...
Status:
US Previously Marketed
First approved in 2015

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Lesinurad (brand name Zurampic) is a urate transporter inhibitor for treating hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In gout patients, Lesinurad lowe...